JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo

This publication has 27 references indexed in Scilit:

• Selecting targets for cancer prevention: where do we go from here?
  Nature Reviews Cancer, 2006
• Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward
  Clinical Cancer Research, 2006
• Methylation in the p21WAF1/cip1 promoter of Apc+/−, p21+/− mice and lack of response to sulindac
  Oncogene, 2005
• c-Jun N-Terminal Protein Kinase 1 (JNK1), but Not JNK2, Is Essential for Tumor Necrosis Factor Alpha-Induced c-Jun Kinase Activation and Apoptosis
  Molecular and Cellular Biology, 2004
• MAP Kinase Signaling Specificity
  Science, 2002
• AP-1 as a regulator of cell life and death
  Nature Cell Biology, 2002
• Requirement of JNK for Stress- Induced Activation of the Cytochrome c-Mediated Death Pathway
  Science, 2000
• SHORT COMMUNICATION: Sulindac suppresses tumorigenesis in the Min mouse
  Carcinogenesis: Integrative Cancer Research, 1996
• JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain
  Published by Elsevier ,1994
• Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain.
  Genes & Development, 1993